Invention Grant
- Patent Title: Neridronic acid for treating bone marrow lesion
-
Application No.: US15360886Application Date: 2016-11-23
-
Publication No.: US09770457B2Publication Date: 2017-09-26
- Inventor: Herriot Tabuteau
- Applicant: ANTECIP BIOVENTURES II LLC
- Applicant Address: US NY New York
- Assignee: ANTECIP BIOVENTURES II LLC
- Current Assignee: ANTECIP BIOVENTURES II LLC
- Current Assignee Address: US NY New York
- Agency: Maschoff Brennan
- Agent Brent A. Johnson; Yuefen Zhou
- Main IPC: A61K31/66
- IPC: A61K31/66 ; A61K31/663 ; A61K9/00 ; A61K45/06 ; A61K9/20 ; A61K31/573 ; A61K31/675
Abstract:
Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, can be used to treat or alleviate pain or related conditions such as bone marrow lesion.
Public/Granted literature
- US20170071958A1 OSTEOCLAST INHIBITORS FOR KNEE CONDITIONS Public/Granted day:2017-03-16
Information query
